

算一算："MATH+" 挽救了生命

作者：Michael Passwater；翻译：李梅；审阅：成长

原文：<http://www.doctoryourself.com/omns/v16n55.shtml#Ref1>

The Chinese translation of this article is made possible by a generous grant from Dr. Bill Grant and from the Cheng Integrative Health.

本文翻译工作得到 Bill Grant 博士资助及上海成氏健康资助。

(OMNS 2020 年 12 月 23 日) 随着 SARS-CoV-2 大流行进入北美，5 名经验丰富的重症监护医生组成了“一线 Covid-19 重症监护联盟”(FLCCC 联盟)。这个最初由危重护理医生 Pierre Kory、G. Umberto Meduri、Jose Iglesias、Joseph Varon 和 Paul Marik 组成的工作组，过去和现在都致力于发展和完善 Covid-19 治疗方案。2017 年，随着静脉注射羟可的松(皮质醇)、抗坏血酸(维生素 C)和硫胺素(维生素 B1)放进标准的脓毒血症护理中，Paul Marik 博士对脓毒血症的治疗方面取得了巨大成功，包括脓毒血症休克。这被称为治疗脓毒血症的“HAT”理论，它是 FLCCC 联盟抗击 Covid-19 的起点。鉴于 Covid-19 的复杂性，“HAT”疗法迅速扩充为“MATH+”，用于 Covid-19 住院患者的护理。

M = 甲基强的松龙;80mg 负荷剂量, 然后 40mg/12h, 至少 7 天, 直到转出 ICU

A = 抗坏血酸;3 g IV /6h, 至少 7 天和/或直到转出 ICU。

T = 硫胺素: 200mg/12h 静脉滴注,

H = 肝素 (低分子量肝素): 皮下注射 1mg /Kg/12h, 禁忌除外

+ = 维生素 D3, 褪黑素, 锌, 镁, 复合维生素 B, 阿托伐他汀, 法莫替丁, 如有需要, 可进行血浆置换治疗

“如果你正在做的事情不起作用, 那就改变你正在做的事情。” (Paul E. Marik

医学博士)

早期干预和避免机械通气也是 2 个关键方面。截至 2020 年 7 月, 实施 MATH+ 方法的两家医院的结果已经完成了同行评审, 现在已在网上公布。他们的发现似乎是奇迹。德克萨斯州休斯顿联合纪念医疗中心的 Joseph Varon 博士的团队截至 7 月份治疗了 140 名住院的 Covid-19 患者, 存活率为 95.6%, 弗吉尼亚州诺福克森塔拉诺福克综合医院的 Paul Marik 博士的团队治疗了 191 名住院的 Covid-19 患者, 存活率为 93.9%。不同的地方是, UMMC 在

急症室开始方案，而诺福克综合医院在重症监护室进行。相比之下，美国、英国和中国的其他 461 家没有使用 MATH+方案的医院公布的生存率从 68%到 84.4%不等。美国疾病控制与预防中心报告称，在 11 月的最后一周，美国有 5000 多名 Covid-19 住院患者，广泛使用 MATH+方案可能意味着未来几个月将增加数千名幸存者。截至 2020 年 12 月 18 日，报告使用部分或全部 MATH+方案的医生数量已经增长到 120 多名。

本文的结论是:

" ...COVID-19 中发现的多种病理生理机制可能需要多种治疗药物协同作用，以抵消这种异常免疫反应的多种有害后果。要找到一颗“灵丹妙药”，甚至一种能在疾病的多个阶段都有效的药物，都是极其不可能的。Math+治疗方案提供了一种廉价的，安全性众所周知的药物组合，这种基于强大的生理学原理和不断增加的临床证据基础，潜在地为 COVID-19 患者的管理提供了一种挽救生命的方法。”

能在医院里存活下来说明治疗效果不错，但如果身体健康到不需要住院治疗就更好了。

FLCCC 联盟开发了用于门诊护理的 I-MASK 协议。10 月，伊维菌素药物加入住院(MATH+)和门诊(I-MASK)方案。伊维菌素是一种廉价、广泛使用的药物，因其抗寄生虫作用获得 2015 年诺贝尔生理学或医学奖。它似乎也是一种有效的抗病毒药物。

这项研究增加了数十份出版物的数量，包括两项与维生素 D 有关的前瞻性随机对照试验，将充足的维生素 D、锌、维生素 C 和/或硒蛋白更好的联合起来用于对抗 Covid-19。

SARS-CoV-2 大流行的发现和警示:

1. 抗坏血酸在对抗已知和未知的传染性病原体时是非常有效的。这一点自 20 世纪 40 年代以来就已经为人所知。Marik 博士最近的工作帮助扩大我们对抗炎和内皮细胞(血管)来自抗坏血酸和皮质醇共同增效作用起到的治疗效果的理解。

- a. 严重的 Covid-19 疾病威胁生命的三个最主要方面是高炎症、高凝和严重缺氧。抗坏血酸对免疫细胞、内皮细胞和气道组织的作用有助于缓解这三个问题。
- b. 在重症监护中，静脉注射皮质醇和抗坏血酸可在几分钟内开始逆转糖蛋白质复合物和内皮细胞损伤。
- c. 定时、定量给药维持一个稳定的状态会更好，因为抗坏血酸的半衰期短，早期干预效果更好，因为白细胞的激活需要依赖高水平的抗坏血酸。在生病期间，每餐服用数克，增加摄入量对抗肠道耐受性是有帮助的。生病的时候，一整天都要服用抗坏血酸，一次摄入的量远远不够。

约瑟夫·瓦伦医生已经连续工作 270 天了。他和他的团队使用 MATH+ 方案，发现 95% 的 Covid-19 患者都能存活。

2. 营养不是单独起作用的;测试单一营养成分效果的观察性和/或干预性研究可能会忽略最佳效益和准确评估所需的混杂因素和协同增效作用。

3. 维持血液浓度 40 - 80 ng/mL 的维生素 D 水平是优化免疫健康的一个主要部分。

a. 维生素 D 是一种强大的激素，影响着 3000 多个基因的表达和功能，是先天和适应性免疫系统的主要组成部分。威尔·泰勒博士已经证明了其中的两个基因，TRXND1 和 GCLC，在 SARS-Cov-2 感染时成为一个重要的部位。他已经证明，病毒抑制和重要的抗氧化剂、DNA 合成调节因子、铁衰竭和内质网应激相关的基因 (TXNRD1, TXNRD3, GCLC, GPX4, SELENOF, SELENOK, SELENOM, SELENOS) 的表达，而维生素 D 显著上调其中两个基因:TXNRD1 和 GCLC 的表达。

b. 对非工业化国家健康部落人口的研究表明，血液维生素 D 水平为 40 ng/mL。

c. 1903 年，尼尔斯·里伯格·芬森(Niels Ryberg Finsen)获得了诺贝尔生理学 and 医学奖，“以表彰他在治疗疾病方面的贡献……通过集中光辐射，他为医学开辟了一条新途径”。

d. 维生素 D 不足和缺乏和不断增加的心血管病的死亡、ICU 死亡和 Covid-19 死亡的风险相关。

- e. 镁是维生素 D 代谢的重要辅助因子（也是生物活性 ATP 的重要辅助因子）。
 - f. 平衡 D3 与维生素 K2 的摄入对最佳的钙代谢和分布很重要。125-250 mcg（5,000-10,000 IU）D3 与 100 mcg K2 MK7 的比值是有益的。
 - g. 肾脏疾病严重损害 D3 和硒蛋白代谢。
4. 在人类生物化学中，维生素 D 和硒的联系非常紧密。
- a. Schutze 博士等人在 1999 年发表的文章指出，需要足量的硒才能帮助维生素 D3 有效上调 TXNRD1 的表达。
 - b. 在人类，D3 和必需氨基酸硒半胱氨酸都必须有足够的量才能有效地产生几种硒蛋白。
 - c. 研究表明，与单独补充 D3 相比，共同补充 D3 和 L-半胱氨酸可改善 GSH、CYP24A1 和维生素 D 调节基因的状态，包括上调 PGC-1 α 、NRF2 和 GLUT-4 基因表达。
 - d. 反过来，谷胱甘肽增加了维生素 D 的循环，增强了维生素 D 的作用。
5. 维生素 D 和硒蛋白是免疫记忆细胞的形成和维持所必需的。不足不仅会增加感染性疾病的风险，也会影响对感染适应性免疫的长久益处。这也可能暗示了对疫苗接种成功的可能性。

6. 在一般人群中，硒浓度为 70 - 150 ng/mL 时可以表现出好的健康状况。血中硒蛋白 P 水平为 4.3 +/- 1.0 mg/L 时有助于 Covid-19 患者预后的改善;将 Zn 和 SELENOP 维持在参考范围内显示生存率高。
7. 微生物理论是有帮助的，但宿主体质仍然是很重要的。营养不足仍然是全球和国家公共卫生的头号敌人。
 - a. 宿主因素影响许多病毒的致病性。许多影响宿主的因素是可以改变的，并且与营养有关。
 - b. 当一些病毒在营养不良的环境中复制时，特别是在缺乏硒的环境中，它们会变异成更有害的毒株。“次级营养不良”是一个未受重视的概念。只要人们营养不良，就有可能继续出现更致命的毒株，而这又使营养不良的人面临病毒突变的风险。
 - c. 对抗感染会大大增加人体的代谢需求。病毒也需要营养;宿主营养和必需蛋白质的窃取和/或破坏进一步影响了人们为消除感染，恢复健康所需要的额外营养。

(Michael Passwater 是美国临床病理学协会认证的医学技术专家，免疫血液学专家，实验室管理文凭。他在临床实验室工作了 28 年，获得了特拉华大学医学技术学士学位。作为理查德·帕斯沃特 (Richard Passwater) 博士的儿子，他从出生前就开始服用维生素 C 和其他营养补充剂。)

References

1. Front Line Covid-19 Critical Care Alliance <https://covid19criticalcare.com>
2. Kory P, Meduri GU, Iglesias J, Varon J, Marik PE. Clinical and Scientific Rationale for the "MATH+" Hospital Treatment Protocol for COVID-19. Journal of Intensive Care Medicine. <https://doi.org/10.1177/0885066620973585>
3. FLCC Alliance (2020) I-MASK+ Protocol. <https://hardball.parkoffletter.org/wp-content/uploads/2020/12/FLCCC-I-MASK-Protocol-v6-2020-12-09-ENGLISH.pdf>
4. The Nobel Prize in Physiology or Medicine 2015. NobelPrize.org. Nobel Media AB 2020. <https://www.nobelprize.org/prizes/medicine/2015/summary>
5. Tay MYF, Fraser JE, Chan WKK, et al. (2013) Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Research. 99:301-306. <https://pubmed.ncbi.nlm.nih.gov/23769930>
6. Varghese FS, Kaukinen P, Gläsker S, et al. (2016) Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Research. 126:117-124. <https://pubmed.ncbi.nlm.nih.gov/26752081>
7. Wagstaff KM, Sivakumaran H, Heaton SM, et al. (2012) Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 443:851-856. <https://pubmed.ncbi.nlm.nih.gov/22417684>

8. King CR, Tessier TM, Dodge MJ, et al. (2020) Inhibition of Human Adenovirus Replication by the Importin alpha/beta1 Nuclear Import Inhibitor Ivermectin. *Journal of Virology*. 94:e00710-20. <https://pubmed.ncbi.nlm.nih.gov/32641484>
9. Caly L, Druce JD, Catton MG, et al. (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 178:104787. <https://pubmed.ncbi.nlm.nih.gov/32251768>
10. Kaufman HW, Niles JK, Kroll MH, Bi C, Holick MF (2020) SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels. *PLoS ONE* 15:e0239252. <https://doi.org/10.1371/journal.pone.0239252>
11. Mercola J, Grant WB, Wagner CL. (2020) Evidence Regarding Vitamin D and Risk of COVID-19 and Its Severity. *Nutrients*, 12:3361. <https://www.mdpi.com/2072-6643/12/11/3361>
12. Zhang J, Taylor EW, Bennett K, Saad R, Rayman MP. (2020) Association between regional selenium status and reported outcome of COVID-19 cases in China. *Am J Clin Nutr*, 111:1297-1299. <https://doi.org/10.1093/ajcn/nqaa095>
13. Moghaddam A, Heller RA, Sun Q, et al. (2020) Selenium deficiency is associated with mortality risk from COVID-19. *Nutrients* 12:2098. <https://doi.org/10.3390/nu12072098>
14. Heller RA, Sun Q, Hackler J et al. (2021) Prediction of survival odds in COVID-19 by zinc, age, and selenoprotein P as composite biomarker. *Redox Biology* 38:101764. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/33126054>

15. Merzon E. (2020) Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. FEBS J. 287:3693-3702. <https://pubmed.ncbi.nlm.nih.gov/32700398>
16. Castillo ME, Costa LME, Barrios JMV, et al. (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105757. <https://pubmed.ncbi.nlm.nih.gov/32871238>
17. Jungreis I, Kellis M. (2020) Mathematical analysis of Cordoba calcifediol trial suggest strong role for vitamin D in reducing ICU admissions of hospitalized COVID-19 patients. MedRxiv preprint. <https://doi.org/10.1101/2020.11.08.20222638>
18. Grassroots Health Nutrient Research Institute. <https://www.grassrootshealth.net>
19. Polonikov, A. (2020) Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis 2020, 6, 7, 1558-1562. <https://doi.org/10.1021/acsinfecdis.0c00288>
20. Horowitz RI, Freeman PR, Bruzzese J. (2020) Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases. Respir Med Case Rep 2020, 101063. <https://doi.org/10.1016/j.rmcr.2020.101063>

21. Zhao B, Fei J, Chen Y, et al. (2014) Vitamin C treatment attenuates hemorrhagic shock related multi-organ injuries through the induction of heme oxygenase-1. BMC Complementary and Alternative Medicine 2014, 14:442-454. <https://pubmed.ncbi.nlm.nih.gov/25387896>
22. Oudemans-van Straaten HM, Spoelstra-de Man AME, de Waard MC. (2014) Vitamin C revisited. Critical Care 18:460-473. <https://pubmed.ncbi.nlm.nih.gov/25185110>
23. Fowler AA, Syed AA, Knowlson S, Natarajan R, et al. (2014) Phase I Safety trial of intravenous ascorbic acid in patients with severe sepsis. Journal of Translational Medicine, 12:32. <https://pubmed.ncbi.nlm.nih.gov/24484547>
24. Gu W, Cheng A, Barnes H, Kuhn B, Schivo M. (2014) Vitamin C Deficiency Leading to Hemodynamically Significant Bleeding. JSM Clinical Case Reports. 2:1046. <http://www.jscimedcentral.com/CaseReports/casereports-2-1046.pdf>
25. Manning J, Mitchell B, Appaduras DA, May JM, et al. (2013) Vitamin C Promotes Maturation of T-Cells. Antioxid Redox Signal. 19:2054-2067. <https://pubmed.ncbi.nlm.nih.gov/23249337>
26. Ladumer A, Schmitt CA, Schachner D, et al. (2012) Ascorbate stimulates endothelial nitric oxide synthase enzyme activity by rapid modulation of its phosphorylation status. Free Radic Biol Med. 2012 May 15; 52:2082-2090. <https://pubmed.ncbi.nlm.nih.gov/22542797>
27. Reddell L, Cotton BA. (2012) Antioxidant and micronutrient supplementation in trauma patients. Curr Opin Clin Nutr Metab Care. 15:181-187. <https://pubmed.ncbi.nlm.nih.gov/22261953>

28. May JM, Qu ZC. (2010) Ascorbic Acid Prevents Increased Endothelial Permeability Caused by Oxidized Low Density Lipoprotein. *Free Radical Res.* 44:1359-1368. <https://pubmed.ncbi.nlm.nih.gov/20815791>
29. Duconge J, Miranda-Massari JR, Gonzalez MJ, et al. (2008) Pharmacokinetics of vitamin C: insights into the oral and intravenous administration of ascorbate. *P R Health Sci J.* 27:7-19. <http://prhsj.rcm.upr.edu/index.php/prhsj/article/view/13>
30. Deicher R, Ziai F, Begknayer C, et al. (2005) Low Total Vitamin C Plasma Level Is a Risk Factor for Cardiovascular Morbidity and Mortality in Hemodialysis Patients. *J Am Soc Nephrol.* 16:1811-1818. <https://pubmed.ncbi.nlm.nih.gov/15814831>
31. Heller R, Munscher-Paulig F, Grabner R, Till V. (1999) L-Ascorbic Acid Potentiates Nitric Oxide Synthesis in Endothelial Cells. *J Biol Chem,* 274:8254-8260. <https://pubmed.ncbi.nlm.nih.gov/10075731>
32. Leibovitz B, Siegel BV. (1978) Ascorbic acid, neutrophil function, and the immune response. *Int J Vitam Nutr Res.* 48:159-164. <https://pubmed.ncbi.nlm.nih.gov/357320>
33. Klenner FR. (1971) Observations on the Dose and Administration of Ascorbic Acid When Employed Beyond the Range of a Vitamin in Human Pathology. *J Applied Nutrition,* 1971, Vol 23:61-87. https://jeffreydachmd.com/wp-content/uploads/2013/07/Ascorbic_Acid_Fred_klenner_1971.pdf

34. Lee RE. (1961) Ascorbic Acid and the Peripheral Vascular System. *Ann N Y Acad Sci.* 92:295-301. <https://pubmed.ncbi.nlm.nih.gov/13760268>
35. Lee RE, Holze EA. (1951) Nutritional factors in hemodynamics: dissociation of pressor response and hemorrhage resistance in avitaminosis C. *Proc Soc Exp. Biol Med.* 76:325-329. <https://pubmed.ncbi.nlm.nih.gov/14827915>
36. McCormick WJ. (1951) Vitamin C in the Prophylaxis and Therapy of Infectious Diseases. *Arch Pediatr*, 68:1-9.
37. Klenner FR. (1949) The Treatment of Poliomyelitis and Other Virus Diseases with Vitamin C. *Journal of Southern Medicine and Surgery*, 111:209-214. <https://pubmed.ncbi.nlm.nih.gov/18147027> https://www.seanet.com/~alexs/ascorbate/194x/klenner-fr-southern_med_surg-1949-v111-n7-p209.htm
38. Klenner FR. (19448) Virus Pneumonia and its Treatment with Vitamin C. *Journal of Southern Medicine and Surgery*, 110:36-38. <https://pubmed.ncbi.nlm.nih.gov/18900646>https://www.mv.helsinki.fi/home/hemila/CP/Klenner_1948_ch.pdf
39. Lee RE, Lee NZ. (1947) The peripheral vascular system and its reactions in scurvy; an experimental study. *Am J Physiol*, 149:465-475. <https://pubmed.ncbi.nlm.nih.gov/20239975>
40. Jungeblut CW. (1935) Inactivation of Poliomyelitis Virus in vitro by Crystalline Vitamin C (Ascorbic Acid). *J Exp Med*, 62:517-521. <https://pubmed.ncbi.nlm.nih.gov/19870431>

41. Colunga Biancatelli RM, Berrill M, Catravas JD, Marik PE. (2020) Quercetin and Vitamin C: An experimental, synergistic therapy for the prevention and treatment of SARS-CoV-2 related disease (COVID-19). *Front Immunol*, 11:1451. <https://pubmed.ncbi.nlm.nih.gov/32636851>
42. Colunga Biancatelli RM, Berrill M, Marik PE. (2020) The antiviral properties of vitamin C. *Expert Rev Anti Infect Ther*, 18:99-101. <https://pubmed.ncbi.nlm.nih.gov/31852327>
43. Barabutis N, Khangoora V, Marik PE, Catravas JD. (2017) Hydrocortisone and Ascorbic Acid synergistically protect and repair lipopolysaccharide-induced pulmonary endothelial barrier dysfunction. *Chest*, 152:954-962. <https://pubmed.ncbi.nlm.nih.gov/28739448>
44. de Melo AF, Homem-de-Mello M. (2020) High-dose intravenous vitamin C may help in cytokine storm in severe SARS-CoV-2 infection. *Crit Care*, 24:500. <https://pubmed.ncbi.nlm.nih.gov/32792018>
45. Marik PE. (2018) Hydrocortisone, Ascorbic Acid and Thiamine (HAT therapy) for the treatment of sepsis. Focus on ascorbic acid. *Nutrients*, 10:1762. <https://pubmed.ncbi.nlm.nih.gov/30441816>
45. May JM, Qu ZC. (2011) Ascorbic acid prevents oxidant-induced increases in endothelial permeability. *Biofactors*, 37:46-50. <https://pubmed.ncbi.nlm.nih.gov/21328627>
46. Utoguchi N, Ikeda K, Saeki K et al. (1995) Ascorbic acid stimulates barrier function of cultured endothelial cell monolayer. *J Cell Physiol*, 163:393-399. <https://pubmed.ncbi.nlm.nih.gov/7706381>

47. Han M, Pendem S, Teh SL, Sukumaran DK, Wu F, Wilson JX. (2010) Ascorbate protects endothelial barrier function during septic insult: Role of protein phosphatase type 2A. *Free Radic Biol Med* 2010; 48:128-35. <https://pubmed.ncbi.nlm.nih.gov/19840845>
48. Khan HMW, Parikh N, Megah SM, Predeteanu GS. (2020) Unusual Early Recovery of a Critical COVID-19 After Administration of Intravenous Vitamin C. *Am J Case Rep*, 21:e925521 <https://pubmed.ncbi.nlm.nih.gov/32709838>
49. Bharara A, Grossman C, Grinnon D, et al. (2016) Intravenous Vitamin C Administered as Adjunctive Therapy for Recurrent Acute Respiratory Distress Syndrome. *Case Rep Crit Care*. 2016;8560871. <https://pubmed.ncbi.nlm.nih.gov/27891260>
50. May JM, Harrison FE. (2013) Role of Vitamin C in the Function of the Vascular Endothelium. *Antioxid Redox Signal*. 19:2068-2083. <https://pubmed.ncbi.nlm.nih.gov/23581713>
51. Marik PE, Khangoora V, Rivera R, et al. (2017) Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. *Chest*, 151:1229-1238. <https://pubmed.ncbi.nlm.nih.gov/27940189>
52. Barabutis N, Khangoora V, Marik PE, Catravas JD. (2017) Hydrocortisone and Ascorbic Acid Synergistically Prevent and Repair Lipopolysaccharide-Induced Pulmonary Endothelial Barrier Dysfunction. *Chest*, 152:954-962. <https://pubmed.ncbi.nlm.nih.gov/28739448>

53. Parker WH, Rhea EM, Qu ZC, Hecker MR, May JM. (2016) Intracellular ascorbate tightens the endothelial permeability barrier through Epac1 and the tubulin cytoskeleton. *Am J Physiol Cell Physiol.* 311:C652-C662. <https://pubmed.ncbi.nlm.nih.gov/27605450>
54. Ferry M, Coley N, Andrieu S, et al. (2013) How to design nutritional intervention trials to populations and apply for efficacy claims: a statement from the international academy on nutrition and aging task force. *J Nutr Heal Aging.* 17:619-523. <https://pubmed.ncbi.nlm.nih.gov/23933873>
55. Bieri JG. (1964) Synergistic effects between antioxidants and selenium or vitamin E. *Biochem Pharmacol.* 13:1465-1470. <https://pubmed.ncbi.nlm.nih.gov/14239620>
56. Badmaev V, Majeed M, Passwater RA. (1996) Selenium: A Quest for Better Understanding. *Altern Ther Health Med.* 2:59-62, 65-67. <https://pubmed.ncbi.nlm.nih.gov/8795924>
57. Taylor, E.W. RNA viruses vs. DNA synthesis: a general viral strategy that may contribute to the protective antiviral effects of selenium. Preprints 2020, 10.20944/preprints202006.0069.v1, 2020060069, <http://doi.org/10.20944/preprints202006.0069.v1>
58. Luxwolda MF, Kuipers RS, Kema IP, Dijck-Brouwer DA, Muskiet FA. (2012) Traditionally living populations in East Africa have a mean serum 25-hydroxyvitamin D concentration of 115 nmol/l. *Br J Nutr.* 108:1557-1561. <https://pubmed.ncbi.nlm.nih.gov/22264449>
59. The Nobel Prize in Physiology or Medicine 1903. NobelPrize.org. Nobel Media AB 2020. <https://www.nobelprize.org/prizes/medicine/1903/summary>
60. Dean C (2017) *The Magnesium Miracle*, 2nd Ed. Ballantine Books. ISBN-13 : 978-0399594441

61. Deng X, Song Y, Manson JE, et al. (2013) Magnesium, vitamin D status and mortality: results from US National Health and Nutrition Examination Survey (NHANES) 2001 to 2006 and NHANES III. BMC Med, 11:187. <https://pubmed.ncbi.nlm.nih.gov/23981518>
62. Flore R, Ponziani FR, Di Rienzo TA, et al. (2013) Something more to say about calcium homeostasis: the role of vitamin K2 in vascular calcification and osteoporosis. Eur Rev Med Pharmacol Sci. 17:2433-2440. <https://pubmed.ncbi.nlm.nih.gov/24089220>
63. Schwalfenberg GK. (2017) Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health. J Nutr Metab. 2017:6254836. <https://pubmed.ncbi.nlm.nih.gov/28698808>
64. Bosworth C, de Boer IH. (2013) Impaired vitamin D metabolism in CKD. Semin Nephrol. 33:158-168. <https://pubmed.ncbi.nlm.nih.gov/23465502>
65. Reinhardt W, Dolff S, Benson S, et al. (2015) Chronic Kidney Disease Distinctly Affects Relationship Between Selenoprotein P Status and Serum Thyroid Hormone Parameters. Thyroid. 25:1091-1096. <https://pubmed.ncbi.nlm.nih.gov/26348725>
66. Schütze N, Fritsche J, Ebert-Dumig R, et al. (1999) The selenoprotein thioredoxin reductase is expressed in peripheral blood monocytes and THP1 human myeloid leukemia cells--regulation by 1,25-dihydroxyvitamin D3 and selenite. Biofactors, 10:329-338, <https://pubmed.ncbi.nlm.nih.gov/10619700>
67. Jain SK, Micinski D. (2013) Vitamin D upregulates glutamate cysteine ligase and glutathione reductase, and GSH formation, and decreases ROS and MCP-1 and IL-8 secretion in high-glucose

exposed U937 monocytes. *Biochem Biophys Res Commun* 437:7-

11, <https://pubmed.ncbi.nlm.nih.gov/23770363>

68. Alvarez JA, Chowdhury R, Jones DP, et al. (2014) Vitamin D status is independently associated with plasma glutathione and cysteine thiol/disulphide redox status in adults. *Clin Endocrinol (Oxf)*

81:458-466. <https://pubmed.ncbi.nlm.nih.gov/24628365>

69. Parsanathan R, Jain SK. (2019) Glutathione deficiency induces epigenetic alterations of vitamin D metabolism genes in the livers of high-fat diet-fed obese mice. *Sci Rep*.

9:14784. <https://pubmed.ncbi.nlm.nih.gov/31616013>

70. Fan YG, Pang ZQ, Wu TY, et al. (2020) Vitamin D deficiency exacerbates Alzheimer-like pathologies by reducing antioxidant capacity. *Free Radic Biol Med*. 161:139-

149. <https://pubmed.ncbi.nlm.nih.gov/33068737>

71. Jain SK, Parsanathan R, Achari AE, et al. (2017) Glutathione Stimulates Vitamin D Regulatory and Glucose Metabolism Genes, Lowers Oxidative Stress and Inflammation, and Increases 25-Hydroxy-Vitamin D Levels in Blood: A Novel Approach to Treat 25-Hydroxyvitamin D Deficiency. *Antioxid Redox Signal*. 29:1792-1807. <https://pubmed.ncbi.nlm.nih.gov/30160165>

72. Guillin OM, Vindry C, Ohlmann T, Chavatte L. (2019) Selenium, Selenoproteins, and Viral

Infection. *Nutrients*, 11:2101. <https://doi.org/10.3390/null092101>

73. Huang Z, Rose AH, Hoffman PR. (2012) The Role of Selenium in Inflammation and Immunity: From Molecular Mechanisms to Therapeutic Opportunities. *Antioxid Redox Signal*. 16:705-743. <https://pubmed.ncbi.nlm.nih.gov/21955027>
74. Cantorna MT, Snyder L, Lin YOD, Yang L. (2015) Vitamin D and 1,25(OH)₂D Regulation of T cells. *Nutrients*, 7:3011-3021. <https://pubmed.ncbi.nlm.nih.gov/25912039>
75. Looman KIM, Jansen MAE, Voortman T, et al. (2017) The role of vitamin D on circulating memory T cells in children: The generation R Study. *Pediatr. Allergy Immunol*. 28:579-587. <https://pubmed.ncbi.nlm.nih.gov/28686349>
76. Taylor EW, Radding W. (2020) Understanding Selenium and Glutathione as Antiviral Factors in COVID-19: Does the Viral M₁ pro Protease Target Host Selenoproteins and Glutathione Synthesis? *Front Nutr* 7:143. <https://pubmed.ncbi.nlm.nih.gov/32984400>
77. Bellinger FP, Ramoy AV, Reeves MA, Berry MJ. (2009) Regulation and function of selenoproteins in human disease. *Biochem J*, 422:11-22. <https://pubmed.ncbi.nlm.nih.gov/19627257>
78. Hiffler L, Rakotoambinina B. (2020) Selenium and RNA viruses interactions: Potential implications for SARS-CoV-2 infection (COVID-19). *Front Nutr*. 7:164. <https://pubmed.ncbi.nlm.nih.gov/33015130>
79. Beck MA, Levander OA, Handy J. (2003) Selenium deficiency and viral infection. *J Nutr*. 133(5 Suppl 1):1463S-1467S. <https://pubmed.ncbi.nlm.nih.gov/12730444>

80. Cunningham-Rundles S, McNeeley DF, Moon A.(2005) Mechanisms of nutrient modulation of the immune response. *J Allergy Clin Immunol.* 115:1119-1128; quiz

1129. <https://pubmed.ncbi.nlm.nih.gov/15940121>

81. Hoffmann PR, Berry MJ. (2008) The influence of selenium on immune responses. *Mol Nutr Food Res.* 52:1273-1280. <https://pubmed.ncbi.nlm.nih.gov/18384097>

82. Taylor AK, Cao W, Vora KP, et al. (2013) Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice. *J Infect Dis.* 207:501-

510. <https://pubmed.ncbi.nlm.nih.gov/22949306>

83. Beck MA, Handy J, Levander OA. (2004) Host nutritional status: the neglected virulence factor. *Trends Microbiol,* 12:417-423. <https://pubmed.ncbi.nlm.nih.gov/15337163>

84. Harthill M. (2011) Review: micronutrient selenium deficiency influences evolution of some viral infectious diseases. *Biol Trace Elem Res.* 143:1325-

1336. <https://pubmed.ncbi.nlm.nih.gov/21318622>

85. Mak TW, Grusdat M, Duncan GS, et al. (2017) Glutathione Primes T cell Metabolism for Inflammation. *Immunity.* 46:675-689, 1089-

1090. <https://pubmed.ncbi.nlm.nih.gov/28423341>, <https://pubmed.ncbi.nlm.nih.gov/28636957>

86. Leibovitz B, Siegel BV. (1978) Ascorbic acid, neutrophil function, and the immune response. *Int*

J Vitam Nutr Res. 48:159-164. <https://pubmed.ncbi.nlm.nih.gov/357320>

87. Manning J, Mitchell B, Appadurai DA, et al. (2013) Vitamin C Promotes Maturation of T-Cells.

Antioxid Redox Signal. 19:2054-2067. <https://pubmed.ncbi.nlm.nih.gov/23249337>

Nutritional Medicine is Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more

information: <http://www.orthomolecular.org>

Find a Doctor

To locate an orthomolecular physician near

you: <http://orthomolecular.org/resources/omns/v06n09.shtml>

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Seth Ayettey, M.B., Ch.B., Ph.D. (Ghana)

Ilyès Baghli, M.D. (Algeria)

Ian Brighthope, MBBS, FACNEM (Australia)

Gilbert Henri Crussol, D.M.D. (Spain)

Carolyn Dean, M.D., N.D. (USA)

Ian Dettman, Ph.D. (Australia)

Damien Downing, M.B.B.S., M.R.S.B. (United Kingdom)

Ron Erlich, B.D.S. (Australia)

Hugo Galindo, M.D. (Colombia)

Martin P. Gallagher, M.D., D.C. (USA)

Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)

William B. Grant, Ph.D. (USA)

Claus Hancke, MD, FACAM (Denmark)

Tonya S. Heyman, M.D. (USA)

Suzanne Humphries, M.D. (USA)

Ron Hunninghake, M.D. (USA)

Bo H. Jonsson, M.D., Ph.D. (Sweden)

Felix I. D. Konotey-Ahulu, MD, FRCP, DTMH (Ghana)

Jeffrey J. Kotulski, D.O. (USA)

Peter H. Lauda, M.D. (Austria)

Thomas Levy, M.D., J.D. (USA)

Alan Lien, Ph.D. (Taiwan)

Homer Lim, M.D. (Philippines)

Stuart Lindsey, Pharm.D. (USA)

Victor A. Marcial-Vega, M.D. (Puerto Rico)

Charles C. Mary, Jr., M.D. (USA)

Mignonne Mary, M.D. (USA)

Jun Matsuyama, M.D., Ph.D. (Japan)

Joseph Mercola, D.O. (USA)

Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)

Karin Munsterhjelm-Ahumada, M.D. (Finland)

Tahar Naili, M.D. (Algeria)

W. Todd Penberthy, Ph.D. (USA)

Selvam Rengasamy, MBBS, FRCOG (Malaysia)

Jeffrey A. Ruterbusch, D.O. (USA)

Gert E. Schuitemaker, Ph.D. (Netherlands)

T.E. Gabriel Stewart, M.B.B.CH. (Ireland)

Thomas L. Taxman, M.D. (USA)

Jagan Nathan Vamanan, M.D. (India)

Garry Vickar, M.D. (USA)

Ken Walker, M.D. (Canada)

Raymond Yuen, MBBS, MMed (Singapore)

Anne Zauderer, D.C. (USA)

Andrew W. Saul, Ph.D. (USA), Editor-In-Chief

Associate Editor: Robert G. Smith, Ph.D. (USA)

Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)

Editor, Chinese Edition: Richard Cheng, M.D., Ph.D. (USA)

Editor, French Edition: Vladimir Arianoff, M.D. (Belgium)

Editor, Norwegian Edition: Dag Viljen Poleszynski, Ph.D. (Norway)

Editor, Arabic Edition: Moustafa Kamel, R.Ph, P.G.C.M (Egypt)

Editor, Korean Edition: Hyoungjoo Shin, M.D. (South Korea)

Assistant Editor: Helen Saul Case, M.S. (USA)

Technology Editor: Michael S. Stewart, B.Sc.C.S. (USA)

Legal Consultant: Jason M. Saul, JD (USA)

Comments and media contact: drsaul@doctoryourself.com OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: <http://www.orthomolecular.org/subscribe.html>

To Unsubscribe from this list: <http://www.orthomolecular.org/unsubscribe.html>